Doug is a trained lawyer with 25-years of experience working on pharmaceutical issues in Canada, including international trade, IP policy, antitrust law and pricing and reimbursement .
Despite the recent passing of legislation of the same name by the Trudeau government, national pharmacare remains as fanciful a prospect in Canada as high-speed rail. This Substack post by Douglas Clark, Agathon Consulting's principal and founder, explains why that is.
